We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
-$54.5M
Cap. Flow
+$154M
Cap. Flow %
10.62%
Top 10 Hldgs %
43.38%
Holding
129
New
42
Increased
32
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$37.6M
2
CYH icon
Community Health Systems
CYH
+$28.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$27.8M
4
CTLT
CATALENT, INC.
CTLT
+$23M
5
MASI
Masimo
MASI
+$18.2M

Top Sells

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$26.7M
2
AMRN
Amarin Corp
AMRN
+$24.9M
3
OGN icon
Organon & Co
OGN
+$21.2M
4
DHR icon
Danaher
DHR
+$17.4M
5
AMN icon
AMN Healthcare
AMN
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.74%
2 Miscellaneous 17.65%
3 Industrials 1.16%
4 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$22.1B
$82M 5.67%
444,471
+1,526
+0.3% +$301K
ASND icon
2
Ascendis Pharma A/S
ASND
$16.3B
$71M 4.91%
445,203
+203,429
+84% +$27.8M
CYH icon
3
Community Health Systems
CYH
$413M
$70.1M 4.85%
5,988,163
+2,166,434
+57% +$28.3M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$69.5M 4.81%
634,670
-32,068
-5% -$3.33M
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$60.1M 4.16%
349,494
+14,449
+4% +$1.89M
AMRN
6
Amarin Corp
AMRN
$295M
$59.2M 4.09%
580,250
-253,224
-30% -$24.9M
GSK icon
7
CALL
GSK
GSK
$102B
$57.5M 3.97%
1,202,960
+80,000
+7% +$4.02M
AZN icon
8
AstraZeneca
AZN
$252B
$53.5M 3.7%
445,404
-47,457
-10% -$5.52M
AVTR icon
9
Avantor
AVTR
$9.86B
$52.8M 3.65%
1,292,014
+317,377
+33% +$12.4M
ARKG icon
10
ARK Genomic Revolution ETF
ARKG
$1.88B
$51.5M 3.56%
689,501
-83,979
-11% -$7.05M
DHR icon
11
Danaher
DHR
$152B
$45.1M 3.12%
166,874
-64,033
-28% -$17.4M
SPY icon
12
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$42.9M 2.97%
100,000
-150,000
-60% -$66.2M
AMRX icon
13
Amneal Pharmaceuticals
AMRX
$6.11B
$36.6M 2.53%
6,849,834
+1,225,109
+22% +$6.17M
LH icon
14
Labcorp
LH
$27.2B
$36.1M 2.5%
+149,354
New +$37.6M
TEVA icon
15
Teva Pharmaceuticals
TEVA
$42.5B
$34.6M 2.39%
3,554,804
-249,601
-7% -$2.34M
NVST icon
16
Envista
NVST
$4.36B
$33.9M 2.34%
810,881
+154,783
+24% +$6.53M
MCK icon
17
McKesson
MCK
$104B
$32.3M 2.23%
161,708
+86,708
+116% +$17.3M
VRTX icon
18
CALL
Vertex Pharmaceuticals
VRTX
$137B
$31.4M 2.17%
173,300
– –
BMY icon
19
Bristol-Myers Squibb
BMY
$136B
$27.8M 1.92%
464,801
-13,527
-3% -$891K
CTLT
20
DELISTED
CATALENT, INC.
CTLT
$24.5M 1.7%
+184,299
New +$23M
ICLR icon
21
Icon
ICLR
$13.1B
$18.8M 1.3%
+71,911
New +$17.5M
MASI
22
DELISTED
Masimo
MASI
$18.1M 1.25%
+67,000
New +$18.2M
OCDX
23
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$16.9M 1.17%
914,986
-479,298
-34% -$9.65M
RCM
24
DELISTED
R1 RCM Inc. Common Stock
RCM
$16.8M 1.16%
764,780
-5,220
-0.7% -$108K
MRVI icon
25
Maravai LifeSciences
MRVI
$1.14B
$16.1M 1.11%
327,810
+252,810
+337% +$12.3M
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Eversept Partners held 129 positions worth $1.45B, down 3.6% from $1.5B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Eversept Partners deployed $154M of net new capital in Q3 2021, opening 42 new positions and adding to 32 existing holdings. Its largest new stake was Labcorp: 149,354 shares worth $36.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Qiagen, an estimated $26.7M trimmed.

  • Eversept Partners's largest Q3 2021 buy was Labcorp: 149,354 shares worth $36.1M.
  • Eversept Partners added most to Community Health Systems in Q3 2021, an estimated $28.3M increase.
  • Eversept Partners's biggest Q3 2021 reduction was Qiagen, cutting an estimated $26.7M.
  • Eversept Partners fully exited Organon & Co in Q3 2021, selling an estimated $21.2M.
  • Eversept Partners's ten largest holdings make up 43% of its $1.45B portfolio in Q3 2021.
  • Eversept Partners opened 42 new positions and closed 24 in Q3 2021.
  • Eversept Partners's portfolio value fell 3.6% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.